Related Experiment Video
Updated: May 18, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
p53 counteracts reprogramming by inhibiting mesenchymal-to-epithelial transition
R Brosh1, Y Assia-Alroy, A Molchadsky
1Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel. ranbroshran@gmail.com
Abstract:
The process of somatic cell reprogramming is gaining increasing interest as reprogrammed cells are considered to hold a great therapeutic potential. However, with current technologies this process is relatively inefficient. Recent studies reported that inhibition of the p53 tumor suppressor profoundly facilitates reprogramming and attributed this effect to the ability of p53 to restrict proliferation and induce apoptosis. Given that mesenchymal-to-epithelial transition (MET) was recently shown to be necessary for reprogramming of fibroblasts, we investigated whether p53 counteracts reprogramming by affecting MET. We found that p53 restricts MET during the early phases of reprogramming and that this effect is primarily mediated by the ability of p53 to inhibit Klf4-dependent activation of epithelial genes. Moreover, transcriptome analysis revealed a large transcriptional signature enriched with epithelial genes, which is markedly induced by Klf4 exclusively in p53(-/-) cells. We also found that the expression of the epithelial marker E-Cadherin negatively correlates with p53 activity in a variety of mesenchymal cells even before the expression of reprogramming factors. Finally, we demonstrate that the inhibitory effect of p53 on MET is mediated by p21. We conclude that inhibition of the p53-p21 axis predisposes mesenchymal cells to the acquisition of epithelial characteristics and renders them more prone to reprogramming. Our study uncovers a novel mechanism by which p53 restrains reprogramming and highlights the role of p53 in regulating cell plasticity.
Insights
Inhibiting the p53-p21 pathway enhances somatic cell reprogramming by promoting mesenchymal-to-epithelial transition (MET). This discovery offers new strategies for improving therapeutic cell generation and understanding cell plasticity.
Area of Science:
- Cell Biology
- Developmental Biology
- Molecular Biology
Background:
- Somatic cell reprogramming holds therapeutic promise but is inefficient.
- Inhibiting the p53 tumor suppressor facilitates reprogramming by limiting proliferation and apoptosis.
- Mesenchymal-to-epithelial transition (MET) is crucial for fibroblast reprogramming.
Purpose of the Study:
- To investigate if p53 impedes reprogramming by affecting MET.
- To elucidate the mechanism by which p53 influences MET during reprogramming.
Main Methods:
- Investigated the role of p53 in MET during early reprogramming phases.
- Utilized transcriptome analysis to identify gene expression changes.
- Assessed the correlation between p53 activity and epithelial marker expression.
- Determined the involvement of p21 in p53's inhibitory effect on MET.
Main Results:
- p53 restricts MET during early reprogramming, primarily by inhibiting Klf4-mediated epithelial gene activation.
- Transcriptome analysis revealed Klf4 induces an epithelial gene signature in p53-deficient cells.
- E-Cadherin expression negatively correlates with p53 activity in mesenchymal cells.
- The p53-p21 axis mediates the inhibition of MET.
Conclusions:
- Inhibiting the p53-p21 axis promotes MET, making mesenchymal cells more receptive to reprogramming.
- This study reveals a novel mechanism of p53-mediated reprogramming restraint.
- Highlights p53's role in regulating cellular plasticity and reprogramming efficiency.
Related Concept Videos
Abnormal Proliferation
Negative Regulator Molecules
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Somatic to iPS Cell Reprogramming
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...

